Unigene Laboratories Inc.

Unigene Laboratories is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and parathyroid hormone- based therapies. The Company’s first U.S. Product, Fortical®, was approved and launched in August 2005. Unigene’s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, parathyroid hormone and insulin. Unigene’s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. Pharmaceutical partners include GlaxoSmithKline, Upsher-Smith Laboratories and Novartis. Unigene has also developed Site-Directed Bone Growth technology which may be able to repair damaged bone, potentially representing a minimally invasive procedure to prevent and treat hip and vertebral compression fractures.